Yuntao Gong

Chief Medical Officer @ Gritgen Therapeutics

About

Nearly 20 years Clinical development/Medical Affairs work experience in MNC pharma/CRO/Biotech, 14 years people management. Worked on multi-TAs as CNS/Pain, Immune diseases, Cancers, COVID-19, Rare diseases, Cardiovascular diseases, AAV gene therapy.

Country

China

City

Chaoyang District

Industry

Pharmaceuticals

Skill

C Level Management, CMO management, Neurodegenerative Disease, Immunology, Rare Diseases, Medical Group Management, Neurology, Business Development, Clinical Trials, Clinical Research, Neuroscience, Medical Affairs, Medical Education, Pharmaceutical Industry, Epidemiology, Clinical Development, Psychiatry, Biotechnology, Medicine, Cardiovascular

Experience

Chief Medical Officer

Gritgen Therapeutics

2025-4 - Present · 1 yr 6 mos

A Chinese innovative gene therapy company focus on rare disease & CNS. The first pipeline as Hemophilia A AAV gene therapy product now into phase 3 stage. More CNS pipelines at early stage.

Chief Medical Offficer

Taimei Intelligence 太美智研

2023-6 - 2025-4 · 1 yr 11 mos

Chaoyang District

A China local clinical CRO company, a subsidary of TaiMei Medical Technology. Responsbile for medical and regulatory team management.

Vice President of Clinical Development

Belief BioMed 信念医药

2021-11 - 2022-11 · 1 yr 1 mo

Beijing, China

China innovative AAV gene therapy biotech with first AAV gene product approved in China for Hemophilia B. I worked there to set up a clinical development team covering clinical research physician, PV, Biometrics. The AAV gene pipeline covering multiple TAs as rare disease, neurodegenerative disorder, and cancer.

VP of Clinical Development

IGNIS Therapeutics (Shanghai) Co., Ltd

2021-5 - 2021-11 · 7 mos

Beijing, China

Ignistherapeutics is a CNS-focused biotech in China. I worked here to set up Clinical research physician & PV team.

Neuroscience Clinical Development Head/Senior Director

Brii Biosciences

2020-4 - 2021-5 · 1 yr 2 mos

Beijing, China

Responsible for US CNS products & Hong Kong COVID-19 neutralized antibodies clinical development covering phase 1 to phase 2 studies.

Medical Director - Clinical Development

PRA Health Sciences

2018-12 - 2020-4 · 1 yr 5 mos

BEIJING

Providing medical/scientific expertise to project team and contributing to the scientific strategic leadership for given therapeutic areas, responsible for medical and safety monitoring on assigned phase 2-3 studies covering immune diseases and cancer.

Theraputic Area Head (Neurology)

Lundbeck

2015-5 - 2018-12 · 3 yrs 8 mos

Beijing

Leading a 7-people Medical Affairs team including Medical Advisors/clinical physician and MSLs to be responsible for TA of Neurology focused on Alzheimer's disease and Parkinson's disease Medical Affairs and clinical development

National MSL Head

Pfizer

2012-10 - 2014-8 · 1 yr 11 mos

Beijing

National MSL Head for Cardiovascular disease (Lipitor/Norvasc/Eliquis) Establish a new MSL team for China cardiovascular therapeutic area

Senior Medical Advisor

Pfizer

2010-4 - 2012-10 · 2 yrs 7 mos

Senior Medical Advisor of CNS & Pain Asia commercial team member (ACT member) of CNS & Pain therapeutic area Medical strategy and marketing strategy development Medical strategy for new product development, clinical trial feasibility evaluation IIT/phase IV studies KOLs management Medical input to support products new indication approval and new product registration in China; attending and presenting in CDE panel meeting.